Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Patients With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

This study is ongoing, but not recruiting participants.
Clalit Health Services
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: August 2, 2010
Last updated: November 1, 2016
Last verified: November 2016
This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in patients with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) receiving first-line therapy for advanced disease. Patients will receive Tarceva at a dose of 150 mg daily orally, with dose adjustments according to protocol depending on toxicity. Anticipated time on study treatment is until disease progression occurs.

Condition Intervention Phase
Non-Squamous Non-Small Cell Lung Cancer
Drug: erlotinib [Tarceva]
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-free survival according to grade of rash; tumor assessments by computer tomography (CT) or magnetic resonance imaging (MRI) according to RECIST criteria [ Time Frame: up to 3 years ]

Secondary Outcome Measures:
  • Rate of Tarceva dose reductions due to grade III-IV rash [ Time Frame: approximately 3 years ]
  • Progression-free survival in patients with Tarceva dose reductions due to grade III-IV rash; tumor assessments by CT or MRI according to RECIST criteria [ Time Frame: up to 3 years ]

Enrollment: 60
Study Start Date: May 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm Drug: erlotinib [Tarceva]
150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Inoperable, locally advanced, recurrent or metastatic (Stage IIIB or IV) non-small cell lung cancer (NSCLC)
  • Presence of epidermal growth factor receptor (EGFR) mutations
  • Previously untreated with any systemic anti-neoplastic therapy for advanced disease
  • Last dose of a prior systemic anti-neoplastic therapy for early-stage disease >/= 4 weeks before study start, and patient recovered from acute toxicities of any previous therapy

Exclusion Criteria:

  • Pregnant or breast feeding women
  • Known allergy or other adverse reaction to study drug or any other related compound
  • Prior systemic anti-neoplastic therapy with HER1/EGFR inhibitors (as small molecule or monoclonal antibody therapy)
  • Newly diagnosed or not yet definitively treated (i.e. stable disease >/= 2 months) CNS metastases or spinal cord compression
  • Any significant ophthalmological abnormality, especially those likely to increase the risk of corneal epithelial lesions (the use of contact lenses is not recommended during the study)
  • Active cancer other than NSCLC, except for basal cell or squamous cell carcinomas of the skin that have been excised and cured
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01174563

Afula, Israel, 18101
Ashkelon, Israel, 78278
Beer Sheva, Israel, 8410101
Haifa, Israel, 34362
Haifa, Israel, 4959381
Holon, Israel, 58100
Jerusalem, Israel, 91120-01
Jerusalem, Israel, 9372212
Kfar-Saba, Israel, 4428164
Nahariya, Israel, 22100
Ramat Gan, Israel, 5262100
Rehovot, Israel, 7610001
Sefad, Israel, 13100
Tel Aviv, Israel, 64239-06
Tiberias, Israel, 15208
Zerifin, Israel, 6093000
Sponsors and Collaborators
Hoffmann-La Roche
Clalit Health Services
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01174563     History of Changes
Other Study ID Numbers: ML25200
Study First Received: August 2, 2010
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 26, 2017